Between March 1, and Sept 15, 2015, we searched the Cochrane Library, PubMed, and Embase with the search term “Alzheimer's Disease” in combination with the terms “pathology”, “imaging”, “diagnosis”, “therapy”, “trials”, “epidemiology”, “CSF”, and “biomarkers” for articles published in any language since Jan 1, 2010. We also searched the reference lists of articles identified by this search strategy and selected those we judged relevant. We largely selected publications from the past 5 years,
SeminarAlzheimer's disease
Introduction
Alzheimer's disease is the main cause of dementia and one of the great health-care challenges of the 21st century. In December, 2013, the G8 stated that dementia should be made a global priority and their ambition that a cure or a disease-modifying therapy should be available by 2025. Research since the discoveries of amyloid β (Aβ) and tau, the main components of plaques and tangles respectively, has provided detailed information about molecular pathogenetic events, yet little is known about the cause of Alzheimer's disease and no curative treatments are available. Furthermore, although the presence of Alzheimer's pathological changes are a sine qua non for diagnosis and sufficient to cause symptoms in some patients, several causes are implicated in patients who become symptomatic aged older than 75 years.
With the advent of modern techniques to image and measure brain processes and analyse big data (including genetic and genomic data), and with governments across the world increasingly prioritising dementia in national health-care agendas, there is hope that the rate of scientific progress will increase. In this Seminar, we present novel, promising findings from the rapidly evolving field of Alzheimer's research, which seem to provide a glimpse into a future when Alzheimer's disease might be cured or—perhaps even more likely—prevented. We describe the clinical context of the disease and novel developments in epidemiology, molecular genetics and pathophysiology, fluid biomarkers, imaging biomarkers, and treatment.
Section snippets
Clinical signs and symptoms
In panel 1, we describe two cases, which show the range of Alzheimer's disease in terms of age and clinical presentation. The first case is a typical presentation of dementia (memory impairment and executive dysfunction interfering with daily life activities)—elderly individuals, who are often on their own and increasingly dependent on others for care. The second is an atypical presentation, and all too often such clinical manifestations are not recognised by primary care doctors and others.
Epidemiology
An estimated 40 million people, mostly older than 60 years, have dementia worldwide, and this figure is projected to double every 20 years, until at least 2050.18 Within these estimates, both the number of people who develop the disease at a specific age and the survival time of those with the disease are assumed to remain stable for a given region. Projected increases in the prevalence of dementia are proportionally much higher for developing countries with young populations than for western
Lifestyle and vascular risk factors
Alzheimer's disease develops over a long preclinical period of several decades, which raises the question of the extent to which risk factors assessed in late life or shortly before onset of clinical symptoms are a result of developing pathological changes rather than a causal relation. Two different approaches have been taken to address this issue. Studies that were started decades ago and included people in early life or midlife allowed assessment of the relations between early-life or
Genetic susceptibility
APOE4 is the major genetic risk factor for Alzheimer's disease. Lifetime risk for Alzheimer's disease is more than 50% for APOE4 homozygotes and 20-30% for APOE3 and APOE4 heterozygotes, compared with 11% for men and 14% for women overall irrespective of APOE genotype.34 APOE4 has several effects on Alzheimer's disease. It interferes with Aβ clearance from the brain,35 and is also processed into neurotoxic fragments.36 Furthermore, mice that express APOE4 show disinhibition of a cyclophilin A
Pathophysiology
The past 30 years of Alzheimer's disease research have produced substantial evidence that accumulation of abnormally folded Aβ and tau proteins in amyloid plaques and neuronal tangles are causally related to neurodegenerative processes in patients' brains.47 Yet observational and pathological studies have generated overwhelming evidence for the complexity and multicausality of dementia.48 This complexity is increasingly recognised in basic and clinical studies too, and research is moving away
Core CSF biomarkers
Core CSF biomarkers for Alzheimer's disease are Aβ42, which shows cortical amyloid deposition; total tau (t-tau), which reflects the intensity of neurodegeneration; and phosphorylated tau (p-tau), which correlates with neurofibrillary pathological changes.70 These core CSF biomarkers have high diagnostic accuracy, with sensitivity and specificity of 85-90%, to identify prodromal Alzheimer's disease in the mild cognitive impairment stage.71, 72 When assessing the diagnostic performance of
Towards an inclusionary approach
Imaging has a key role in the clinical assessment of patients with suspected Alzheimer's disease. The traditional view that at least one structural scan (either CT or MRI) should be done at least once in every patient with cognitive impairment to rule out intracranial causes (eg, meningioma, subdural haematoma) has been complemented by the notion that the demonstration of regional atrophy in the medial temporal region can provide positive diagnostic information (panel 1).94 A visual scale
Treatment
The mainstay of treatment for Alzheimer's disease is supportive care from family and other caregivers. Patients with dementia have better quality of life in a predictable home environment that meets their daily needs. Familial caregivers need help to learn how to manage the progressive nature of the illness and guidance on how to mobilise the resources needed to maintain care for their loved one while preserving their own wellbeing.
Four drugs are used for the treatment of the dementia phase:
Secondary prevention, risk reduction, and other approaches
Several major trials investigating how to delay the onset of cognitive decline in individuals at high risk for Alzheimer's disease are underway. The Anti-Amyloid in Asymptomatic Alzheimer's disease (A4) study is testing whether solanezumab given monthly for 3 years could delay cognitive decline in cognitively healthy elderly patients with a positive amyloid PET scan.127 Four studies aiming to delay cognitive decline in individuals with high genetic risk are underway, two in families with a
Conclusions
Alzheimer's research is rapidly progressing. Advances in basic science and molecular diagnostics have provided unprecedented possibilities for drug development. In the aftermath of the G8 statement, there is no time to waste in trying to provide a better future for the patients of tomorrow, although improving care and help for today's patients should always remain a priority.
If progress accelerates as expected, a patient with early symptoms of Alzheimer's disease in 2025 will be treated
Search strategy and selection criteria
References (142)
- et al.
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Alzheimers Dement
(2011) - et al.
Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele
Lancet Neurol
(2011) - et al.
Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study
Lancet Neurol
(2011) - et al.
Alzheimer's disease first symptoms are age dependent: evidence from the NACC data set
Alzheimers Dement
(2015) - et al.
Shining a light on posterior cortical atrophy
Alzheimers Dement
(2013) - et al.
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Lancet Neurol
(2014) - et al.
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Alzheimers Dement
(2011) - et al.
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Alzheimers Dement
(2011) - et al.
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Lancet Neurol
(2013) - et al.
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
Alzheimers Dement
(2014)
Cerebrospinal fluid Abeta42 is the best predictor of clinical progression in patients with subjective complaints
Alzheimers Dement
Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990–2010: a systematic review and analysis
Lancet
Epidemiology of dementia in Asia: insights on prevalence, trends and novel risk factors
J Neurol Sci
Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study
Lancet Diabetes Endocrinol
Influence of population versus convenience sampling on sample characteristics in studies of cognitive aging
Ann Epidemiol
Potential for primary prevention of Alzheimer's disease: an analysis of population-based data
Lancet Neurol
Apolipoprotein E sets the stage: response to injury triggers neuropathology
Neuron
Genetics of Alzheimer's disease
Neurotherapeutics
Alzheimer's disease risk genes and mechanisms of disease pathogenesis
Biol Psychiatry
Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease
Cell
A Genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology
Cell Rep
Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis
Neuron
Distinct tau prion strains propagate in cells and mice and define different tauopathies
Neuron
Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein
Neuron
The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo
J Biol Chem
Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice
J Biol Chem
Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions
Biol Psychiatry
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study
Lancet Neurol
Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic
Alzheimers Dement
CSF biomarker variability in the Alzheimer's Association quality control program
Alzheimers Dement
Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease
Biochem Pharmacol
New ELISAs with high specificity for soluble oligomers of amyloid beta-protein detect natural Abeta oligomers in human brain but not CSF
Alzheimers Dement
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease
Alzheimers Dement
The future of blood-based biomarkers for Alzheimer's disease
Alzheimers Dement
Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research
Alzheimers Dement
The EADC-ADNI harmonized protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity
Alzheimers Dement
Delphi definition of the EADC-ADNI harmonized protocol for hippocampal segmentation on magnetic resonance
Alzheimers Dement
Training labels for hippocampal segmentation based on the EADC-ADNI harmonized hippocampal protocol
Alzheimers Dement
Dementia in western Europe: epidemiological evidence and implications for policy making
Lancet Neurol
Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease
Ann Neurol
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease
Neurology
Age, sex, and APOE ɛ4 effects on memory, brain structure, and beta-amyloid across the adult life span
JAMA Neurol
Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment
Arch Gen Psychiatry
Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment
Neurology
The global prevalence of dementia: a systematic review and metaanalysis
Alzheimers Dement
Estimating the burden of early onset dementia; systematic review of disease prevalence
Eur J Neurol
Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study
Neurology
New insights into the dementia epidemic
N Engl J Med
Period, birth cohort and prevalence of dementia in mainland China, Hong Kong and Taiwan: a meta-analysis
Int J Geriatr Psychiatry
Prevalence and trends of dementia in Korea: a systematic review and meta-analysis
J Korean Med Sci
Cited by (2308)
In silico exploration of CB2 receptor agonist in the management of neuroinflammatory conditions by pharmacophore modeling
2024, Computational Biology and ChemistryInhibitory effects of β-asarone on lncRNA BACE1-mediated induction of autophagy in a model of Alzheimer's disease
2024, Behavioural Brain ResearchThe association of glucose metabolism measures and diabetes status with Alzheimer's disease biomarkers of amyloid and tau: A systematic review and meta-analysis
2024, Neuroscience and Biobehavioral ReviewsEfficacy and safety of repetitive Transcranial Magnetic Stimulation and transcranial Direct Current Stimulation in memory deficits in patients with Alzheimer's disease: Meta-analysis and systematic review
2024, International Journal of Clinical and Health PsychologyInteractions between nanoparticles and pathological changes of vascular in Alzheimer's disease
2024, Advanced Drug Delivery Reviews